Evotec to acquire Gates Foundation-backed Just Biotherapeutics

This buyout adds to Evotec's growing spate of deals with the likes of Sanofi, Celgene and Novo Nordisk over the past year. (Evotec)

Biotech-CRO hybrid Evotec is continuing its deals, buys and collaborations strategy with its acquisition of U.S. biologics company Just Biotherapeutics.

The German company is spending a small sum, just $90 million, on its latest purchase, but boosts its offering in biologics oncology, central nervous system disorders, pain, inflammation, metabolics and infectious diseases.

Just Bio works on tech for design, development and manufacturing of biologics. Evotec gains the company's expertise, 90 employees and its discovery, development and manufacturing facility in Seattle.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

The CDMO came into public life in the summer of 2016 with a simple idea: Breakthrough biologics aren’t for everyone. They’re typically priced so that their use is confined to insured patients in the U.S. and Europe, in addition to wealthy self-paying patients around the world.

So, the Seattle startup launched to change that with a team lifted from major biologics and biosimilars player Amgen as well as major financial backing from the Bill & Melinda Gates Foundation along with Merck, Lilly Asia Ventures and ARCH Venture Partners

In a nutshell, Just Bio aims to reduce the costs that restrict access to therapeutic proteins for most patients who need them. It’s focused specifically on new designs to create better therapeutic molecules at more efficient manufacturing plants. And this aim is not just to make products for the developing world, but for also for use in developed nations.

This adds to the growing catalog of deals Evotec has penned over the years, including a $65 million cancer drug pact with Celgene signed last May, a preclinical diabetes pact with Novo Nordisk in August and a deal to buy up Sanofi’s infectious disease business for $70 million last summer.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.